

21ST



PGDIS CONFERENCE



6-8 May 2024
Kuala Lumpur
Malaysia

PGT and
BEYOND...



Multiomic integration of transcriptome and genome analysis to enable novel biomarker discovery

Linbo Zhao, Nao Yasuyama, Ayaka Shimokawa, Arjun Vadapalli, Jay Kim, Mohammad Fallahi, Matt Rowe, Victor Tek, Kajal Choudhary, Hui Helen Xu, Andrew Farmer

Takara Bio USA, 2560 Orchard Pkwy, San Jose, California, 95131

For Research Use Only. Not for use in diagnostic procedures.

© 2024 Takara Bio Inc. All rights reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Additional product, intellectual property, and restricted use information is available at takarabio.com.

that's
GOOD
science!®

Takara Bio: core capabilities



that's
GOOD
science!®

NGS

- SMARTer® and SMART-Seq® RNA-seq library preparation kits
- PicoPLEX® and ThruPLEX® DNA-seq library preparation kits

PCR, qPCR, RT-PCR

- TaKaRa Ex Premier™, LA Taq™, PrimeSTAR® GXL, SeqAmp™, Titanium® polymerases, & PrimeScript™ RT
- EcoDry™ lyophilized enzymes and kits

Cloning

- In-Fusion® Snap Assembly Cloning

Nucleic acid purification

Gene delivery

- Lenti-X™, Adeno-X™, Retro-X™, and AAVpro® systems | Xfect™ transfection reagent
- RetroNectin® reagent

Functional genomics

- Tet systems and iDimerize™ systems
- Guide-it™ CRISPR/Cas9 genome editing products
- Living Colors® fluorescent proteins

Protein expression & purification

- TALON® and His60 Ni protein purification

OEM

New biomarkers beyond copy number status to improve embryo selection

Looking beyond PGT-A to obtain a fuller picture

- PGT-A may fail to produce interpretable results in up to 5.7% cases*
- DNA copy number provides only partial insights

Comprehensive understanding of the molecular landscape requires multiomic approaches

- DNA-seq: genetic makeup; including copy number, single nucleotide, and structural variants
- RNA-seq: gene expression patterns, transcriptional profiles, single nucleotide variants
- Other omics



PicoPLEX technology

- Highly reproducible whole genome amplification
- Quasi-random priming + suppression PCR
- Widely used in PGT-A workflows around the world




SMART-Seq technology

- Full-length transcript information
- Highest sensitivity and uniform gene-body coverage
- Industry gold standard for low-input and single-cell RNA-seq

*Benjamin S. Harris, et al. Preimplantation genetic testing: a review of current modalities. *F&S Reviews* 2, 43-56 (2021).

Multiomic workflow for genome and transcriptome analysis

- A tailored method for combined PGT-A and differential expression analysis
- >95% success rate (passing combined QC criteria for PGT-A and RNA-seq), improved from 75.6% in the original publication*
- Accompanying bioinformatic analysis solutions
 - PGT-A: Embgenix™ Analysis Software
 - RNA-seq: Cogent™ NGS analysis pipeline





*Macaulay, I. et al. G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. *Nat Methods* **12**, 519-522 (2015).

Analysis methods for lymphoblastoid cells

- Starting material:
 - GM08331 cell line (Coriell Institute)
 - Male, 46, XY, del(13)(q32q33)
 - 12.1 Mb deletion
- Experimental workflow:
 - Five cells were sorted into independent wells of a 96-well PCR plate
 - 12 replicate samples were processed using the multiomic workflow
 - Libraries were sequenced on an Illumina® NextSeq® using 2 x 75 bp paired-end (PE) reads
 - Data were down-sampled to 1.5×10^6 reads (750,000 PE clusters) for DNA-seq results and 4×10^6 reads (2×10^6 PE clusters) for RNA-seq results



Reproducible results for CNV analysis



Del(13)(q32q33) was reported for all replicates by Embgenix Analysis Software, indicating that the sensitivity and specificity for detection of CNVs ≥ 10 Mb at 1.5×10^6 reads was comparable to the standalone PGT-A assay.

Uncompromised sensitivity and data quality for mRNA analysis

- Data analysis with Cogent NGS analysis pipeline at 4M reads per sample
- Unbiased gene body coverage with >10,000 genes detected and >70% of reads within exons




Reproducible transcriptomic profiles

- High correlation in gene counts across experimental replicates
 - RNA-seq results analyzed with Cogent NGS analysis pipeline
 - Pearson correlation >0.95 for all comparisons

Gene count: Pearson correlations

| | | | | | | | | | | | | |
|--------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|--------|------|
| cDNA1 | 1.00 | 0.98 | 0.98 | 0.99 | 0.98 | 0.98 | 0.98 | 0.96 | 0.99 | 0.97 | 0.95 | 0.97 |
| cDNA2 | 0.98 | 1.00 | 0.97 | 0.98 | 0.97 | 0.99 | 0.99 | 0.97 | 0.99 | 0.98 | 0.96 | 0.98 |
| cDNA3 | 0.98 | 0.97 | 1.00 | 0.98 | 0.98 | 0.96 | 0.98 | 0.97 | 0.97 | 0.97 | 0.96 | 0.97 |
| cDNA4 | 0.99 | 0.98 | 0.98 | 1.00 | 0.98 | 0.98 | 0.99 | 0.96 | 0.98 | 0.98 | 0.96 | 0.97 |
| cDNA5 | 0.98 | 0.97 | 0.98 | 0.98 | 1.00 | 0.98 | 0.98 | 0.97 | 0.97 | 0.98 | 0.97 | 0.97 |
| cDNA6 | 0.98 | 0.99 | 0.96 | 0.98 | 0.98 | 1.00 | 0.98 | 0.97 | 0.99 | 0.98 | 0.97 | 0.98 |
| cDNA7 | 0.98 | 0.99 | 0.98 | 0.99 | 0.98 | 0.98 | 1.00 | 0.98 | 0.98 | 0.99 | 0.97 | 0.98 |
| cDNA8 | 0.96 | 0.97 | 0.97 | 0.96 | 0.97 | 0.97 | 0.98 | 1.00 | 0.96 | 0.99 | 0.97 | 0.96 |
| cDNA9 | 0.99 | 0.99 | 0.97 | 0.98 | 0.97 | 0.99 | 0.98 | 0.96 | 1.00 | 0.97 | 0.96 | 0.98 |
| cDNA10 | 0.97 | 0.98 | 0.97 | 0.98 | 0.98 | 0.98 | 0.99 | 0.99 | 0.97 | 1.00 | 0.97 | 0.97 |
| cDNA11 | 0.95 | 0.96 | 0.96 | 0.96 | 0.97 | 0.97 | 0.97 | 0.96 | 0.97 | 0.97 | 1.00 | 0.96 |
| cDNA12 | 0.97 | 0.98 | 0.97 | 0.97 | 0.97 | 0.98 | 0.98 | 0.96 | 0.98 | 0.97 | 0.96 | 1.00 |
| cDNA1 | cDNA2 | cDNA3 | cDNA4 | cDNA5 | cDNA6 | cDNA7 | cDNA8 | cDNA9 | cDNA10 | cDNA11 | cDNA12 | |

Gene count: scatter plot



Analysis methods for trophectoderm biopsy samples

- Starting material:
 - Two trophectoderm (TE) biopsy samples were taken from each of three previously characterized embryos; samples were directly lysed and stored in sample lysis buffer
 - Embryo 1: Monosomy 21, XY
 - Embryo 2: Trisomy 18 & 20, XY
 - Embryo 3: Trisomy 4, XX
- Experimental setup:
 - Six TE biopsy samples were processed with the multiomic workflow
 - DNA-seq and RNA-seq libraries were sequenced on a NextSeq® platform using 2 x 75 bp paired-end (PE) reads
 - Data were down-sampled to 1.5×10^6 reads (750,000 PE clusters) for DNA-seq results, and 4×10^6 reads (2×10^6 PE clusters) for RNA-seq results


Concordant CNV calls between multiomic analysis and initial PGT-A findings

| SAMPLE ID | Embryo 1-1 | Embryo 1-2 | Embryo 2-1 | Embryo 2-2 | Embryo 3-1 | Embryo 3-2 |
|----------------------------------|-----------------|-----------------|---------------------------|---------------------|----------------|----------------|
| REFERENCE LAB RESULT | Monosomy 21, XY | Monosomy 21, XY | Trisomy 18 & 20, XY | Trisomy 18 & 20, XY | Trisomy 4, XX | Trisomy 4, XX |
| QC STATUS | PASS | PASS | PASS | PASS | PASS | PASS |
| SAMPLE CALL INTERPRE-TATION | Aneuploid | Aneuploid | Aneuploid | Aneuploid | Aneuploid | Aneuploid |
| NUMBER OF TOTAL READS | 1,500,000 | 1,500,000 | 1,500,000 | 1,500,000 | 1,500,000 | 1,500,000 |
| SEX | Male | Male | Male | Male | Female | Female |
| KARYOTYPE | 45,XY,seq(21)x1 | 45,XY,seq(21)x1 | 48,XY,seq(18)x3,seq(20)x3 | 47,XY,seq(20)x3 | 47,XX,seq(4)x3 | 47,XX,seq(4)x3 |
| Concordant with standalone PGT-A | YES | YES | YES | YES | YES | YES |


Embryo 1-1




Embryo 1-2




Embryo 2-1



Embryo 2-2





Embryo 3-1



Embryo 3-2





Uncompromised sensitivity and data quality for mRNA analysis from TE biopsy samples




Detecting chromosome-level copy number variation and allelic imbalance using transcriptomic data

CNV detection using transcript counts

- Chromosome copy number
- Aneuploidy detected
- Sex chromosome calling



SNV-based detection of allelic imbalance using RNA-seq. Can also be used to detect polyploidy, UPD, etc.



Conclusions

- We have demonstrated the feasibility of obtaining both genome and transcriptome information from a single biopsy sample by integrating Embgenix and SMART-Seq workflows in a manner that minimizes genomic DNA loss and RNA contamination
- Leveraging transcriptome analysis for discovery of novel biomarkers in this context provides a dynamic and functional view of the embryo, providing a basis for potential improvements to ART

To discuss early access opportunities involving this technology, please contact:

Victor Tek
victor_tek@takarabio.com
+1 650.919.7512

Linbo Zhao
linbo_zhao@takarabio.com
+1 650.919.7337



that's
GOOD
science!®

PGDIS 2024